Frank Kensy has a diverse work experience in the field of biotechnology and bioengineering. Frank is currently the Managing Director & Co-Founder of b.fab GmbH, a company specializing in the conversion of CO2 and renewable energy into biotechnological value chains. Prior to this, they worked at Smart Bioprocess as a Biotech Consulting & Innovation Management consultant, where they provided guidance in bioprocess development and innovation management for industrial and pharmaceutical biotechnology companies.
Before that, Frank Kensy served as the Managing Director & Co-Founder of m2p-labs GmbH, a venture-backed company focused on microbioreactor technology for accelerated bioprocess development. Frank played a key role in establishing the company as a leading developer and supplier of microbioreactors globally.
Frank Kensy's earlier experience includes working as a Research Assistant & PhD Student at RWTH Aachen University and as a Scientist and Leader of the Fermentation Group at Rhein Biotech N.V. At Rhein Biotech, they led the fermentation group and contributed to the development of biopharmaceutical and technical enzyme processes.
Frank Kensy attended RWTH Aachen University from 2002 to 2006. During this time, they pursued a Promotion/PhD degree in the field of Biochemical Engineering.
Org chart
Teams
This person is not in any teams
Offices
This person is not in any offices
b.fab GmbH
B.fab specializes in the conversion of CO2 and hydrogen from renewable energy into biotechnological value chains.It utilizes formate as its central mediator to bind and store CO2 and H2 (made from water) in liquid form. The company's bioprocesses start with the feedstock formate and it uses synthetic biology to design specific pathways andto convert formate into value-added chemicals. The platform is built on anaerobic and aerobic microbial production hosts to provide flexibility in the process design and adaptation to specific product requirements. B.fab GmbH applies laboratory automation, high-throughput experimentation, and advanced bioprocess development in an agile environment to develop new bioprocesses efficiently and in a minimal time frame. It was founded in 2018 in Dortmund, Nordrhein-Westfalen.
